Prostate Cancer
Conditions
Keywords
adenocarcinoma of the prostate, recurrent prostate cancer
Brief summary
RATIONALE: Gene mutations may make prostate cancer cells unable to attach to androgens. This may permit the growth of prostate cancer. Gene testing may improve the identification of patients with advanced prostate cancer. PURPOSE: Clinical trial to study the androgen receptor gene in patients with prostate cancer that is not responsive to hormone therapy.
Detailed description
OBJECTIVES: 1. the feasibility of collecting bone marrow biopsies from prostate cancer patients in a cooperative group setting 2. the incidence of marrow invasion by prostate tumor in random bone marrow biopsy 3. the influence of previous prostate radiation on obtaining prostate tumor 4. the frequency and type of AR mutations and 5. association of AR mutations with response to antiandrogen withdrawal.
Interventions
OTHERmutation analysis
Sponsors
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Healthy volunteers
No
Inclusion criteria
1. Histologically proven adenocarcinoma of the prostate that is refractory to hormone therapy 2. Patients who are eligible for anticancer therapy on Protocol CLB-9480, CLB-9583, CLB-9680, or CLB-9780 are also eligible for this study if they have not started treatment on those protocols
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival | Up to 10 years |
Secondary
| Measure | Time frame |
|---|---|
| response rate | Up to 10 years |
Countries
United States
Outcome results
None listed